The downsizing of health federal agencies comes after Trump threatened to pull the US out of the World Health Organisation (WHO) and shut down USAID, the world's largest donor of humanitarian aid ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

B, consensus $58.91B. The company said, “The company anticipates 2025 revenue to be between $58.0 billion and $61.0 ...